Positive results announced in phase 2a trial of take-home microdosing drug for depression
Key takeaways:
- MB22001 is a proprietary self-titratable form of LSD in microdoses for take-home use.
- Patients experienced a 60% reduction in depressive symptoms and 53% had a complete remission from depression.
MindBio Therapeutics has announced positive topline results from its take-home phase 2a clinical trial of MB22001 in patients with depression, according to a company press release.
A proprietary self-titratable form of lysergic acid diethylamide (LSD) in microdoses for take-home use, the novel therapeutic allows patients to dose up or down depending on their tolerance.
Image: Adobe Stock
“We are delighted to share that MB22001 showed rapid and statistically significant improvements with 60% reduction in depressive symptoms and 53% of patients experiencing complete remission from depression,” MindBio CEO Justin Hanka said in the release.
The trial achieved its primary efficacy endpoint, with “an impressive mean 14.1 point drop in Montgomery-Asberg Depression Rating Scale (MADRS),” Hanka added.
Additionally, the trial demonstrated safety and tolerance, with no serious treatment-related adverse events, according to the release.